PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26377792-5	2015	OAT1 (IC50: 23.7 muM), OAT2 (IC50: 9.5 muM), and OAT3 (IC50: 1.6 muM) were potently inhibited by MK571, an established multidrug resistance protein inhibitor.	verlukast	97-102	latexin	Homo sapiens	39-42	
26377792-5	2015	OAT1 (IC50: 23.7 muM), OAT2 (IC50: 9.5 muM), and OAT3 (IC50: 1.6 muM) were potently inhibited by MK571, an established multidrug resistance protein inhibitor.	verlukast	97-102	latexin	Homo sapiens	17-20	
26377792-5	2015	OAT1 (IC50: 23.7 muM), OAT2 (IC50: 9.5 muM), and OAT3 (IC50: 1.6 muM) were potently inhibited by MK571, an established multidrug resistance protein inhibitor.	verlukast	97-102	latexin	Homo sapiens	39-42	
26239185-6	2015	The pan-multidrug resistance-associated protein (MRP) inhibitor MK-571 at 20 muM essentially abolished cellular excretion of both H-3"-S and H-7-S (the excretion activities were only 6% of the control), whereas the breast cancer resistance protein-selective inhibitor Ko143 had no effects on sulfate excretion.	verlukast	64-70	latexin	Homo sapiens	77-80	
31133859-6	2019	A chemical inhibitor, MK571 (5 and 20 muM), a pan-MRP inhibitor, led to a significant decrease in excreted G1 (maximal 59.1%) and G2 levels (maximal 42.4%), whereas Ko143 (5 and 20 muM), a selective BCRP inhibitor, caused moderate downregulation of excreted G1 (maximal 29.4%) and G2 (maximal 28.5%).	verlukast	22-27	latexin	Homo sapiens	38-41	
31133859-6	2019	A chemical inhibitor, MK571 (5 and 20 muM), a pan-MRP inhibitor, led to a significant decrease in excreted G1 (maximal 59.1%) and G2 levels (maximal 42.4%), whereas Ko143 (5 and 20 muM), a selective BCRP inhibitor, caused moderate downregulation of excreted G1 (maximal 29.4%) and G2 (maximal 28.5%).	verlukast	22-27	latexin	Homo sapiens	181-184